Table 1

Patients characteristics of patients with heart failure between 2002 and 2015

Overall2002–20052006–20082009–20122013–2015% missing
n85 73225 36617 71526 11416 537
Demographics
 Age (years, median (IQR))79.1(70.2, 85.7)78.7(70.7, 84.9)78.7(69.9, 85.4)79.5(70.1, 86.3)79.7(70.0, 86.4)0
 Sex (% women)48.649.348.448.448.00
 Ethnicity (% Caucasian)96.597.596.996.195.13.5
 Social deprivation* (% lowest quintile)24.325.125.024.022.90
Clinical and lifestyle measurements
 SBP (mm Hg, mean (SD))136.2 (20.7)140.6 (22.3)135.9 (20.7)134.6 (20.0)132.9 (18.7)13.0
 DBP (mm Hg, mean (SD))76.2 (12.0)78.4 (12.0)76.2 (12.0)75.4 (12.0)74.4 (11.6)13.0
 BMI (kg/m2, mean (SD))28.6 (6.6)28.2 (6.4)28.4 (6.6)28.7 (6.8)28.8 (6.8)54.0
 eGFR (min/m2/1.73 mL, median (IQR))58.4(45.3, 72.1)54.7(43.4, 66.1)56.5(44.3, 68.8)60.5(46.3, 75.3)62.9(47.5, 78.2)24.0
 Smoking status (% current)20.822.320.020.420.538.7
Medical history (%)†‡
 Atrial fibrillation36.628.436.340.643.0
 COPD17.914.817.319.521.0
 Diabetes22.318.122.223.726.7
 Hypertension60.746.060.767.972.0
 Ischaemic heart disease44.239.046.046.446.8
 Valvular disease16.59.514.919.923.8
Medication prescription up to 3 months after HF diagnosis (%)‡
 RAS inhibitors60.859.663.562.057.6
 Beta blockers42.528.941.049.354.1
 MR-antagonists18.018.417.917.618.2
 Loop diuretics63.068.463.561.157.0
  • *Assessed by index of multiple deprivation.

  • †Denotes prior medical history of given comorbidity.

  • ‡Medical conditions and prescriptions were considered absent if not recorded.

  • BMI, body mass index; COPD, chronic obstructive pulmonary disease; CPRD, clinical practice research datalink; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; MR, mineralocorticoid receptor; RAS inhibitors, angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers; SBP, systolic blood pressure.